EXAMS · SÃO PAULO
BRCA1 and BRCA2 MLPA: test cost, purpose and procedure
A genetic test that looks for entire sections that are missing or repeated in two genes linked to breast and ovarian cancer risk.

Understand the exam
BRCA1 and BRCA2 are genes that produce proteins that help repair DNA damage. When a person inherits a harmful change in one of these genes, the risk of certain cancers increases, mainly breast and ovarian cancer, but also other types.
These changes may be small mutations or large rearrangements in the gene. MLPA, which stands for multiplex ligation-dependent probe amplification, is a test used to find deletions and duplications of parts of the gene.
That is why MLPA may be done after sequencing, when no small change was found, to also assess large changes in the BRCA1 and BRCA2 genes.
How it is done
Testing of the BRCA1 and BRCA2 genes can be done with a blood or saliva sample, from which the laboratory extracts DNA. The team confirms the sample type and any preparation needed when you book.
The result is a report stating whether a large change was found in the genes analyzed. It should be explained by the doctor who ordered the test or during a genetic counseling appointment.
When it is recommended
- Personal or family history of breast cancer at age 50 or younger
- Recent breast cancer diagnosis at age 65 or younger (an indication for BRCA1 and BRCA2 gene testing)
- Personal or family history of ovarian cancer, male breast cancer, pancreatic cancer, or metastatic or high-risk prostate cancer
- A relative with a known harmful inherited change in the BRCA1 or BRCA2 genes
- BRCA1 and BRCA2 sequencing with no small change found, in a person with breast cancer
Does the exam hurt?
If a blood sample is used, you may feel a small prick when the needle goes in or comes out.
After the exam
Cost and health plans
| Exam | Self-pay | Duration | Health plans |
|---|---|---|---|
| BRCA 1 and 2 MLPA | Starting at R$ 2,376.00 (≈ US$ 415, estimated) | Confirm with the team | Ask the team about coverage |
The team confirms the requested option, coverage, and conditions before booking.
Book an examFrequently asked questions
What is the difference between MLPA and BRCA sequencing?
Sequencing reads the gene sequence and is used to look for small changes. MLPA measures the amount of parts of the gene and looks for entire sections that are missing or duplicated. That is why one test usually complements the other.
Do I need to fast for BRCA MLPA?
The clinic has no recorded preparation instructions for this test. The team provides guidance when scheduling, especially if the same order includes other tests.
If the result is normal, am I free of risk?
Not necessarily. A normal MLPA result shows that no large change was found in these two genes. A negative result does not mean a person will not develop cancer: the risk also depends on family history, and your doctor evaluates the full picture.
What happens if a change is found?
If a harmful inherited change is found, your doctor may discuss options to reduce risk, such as more intensive screening, risk-reducing surgery and medications to lower risk. The result can also be shared with blood relatives to help them better understand their own cancer risk.
How long until the results are ready?
Genetic test turnaround varies by laboratory and is not listed on this page. The team explains it when assisting you.
Does my health plan cover BRCA1 and BRCA2 MLPA?
See the table on this page for plans with listed coverage. If your plan is not listed, the team confirms coverage for you.
Where we see patients
References
- National Cancer Institute (NCI). BRCA Gene Changes: Cancer Risk and Genetic Testing. NCI. 2024.
- Sahin I, Saat H. A novel BRCA1 duplication and new insights on the spectrum and frequency of germline large genomic rearrangements in BRCA1/BRCA2. Mol Biol Rep. 2021.
- Seong MW et al. A multi-institutional study of the prevalence of BRCA1 and BRCA2 large genomic rearrangements in familial breast cancer patients. BMC Cancer. 2014.
- Hogervorst FB et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res. 2003.
- Bedrosian I et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol. 2024.
This content is informational and does not replace a consultation.
Updated on